V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015809 | 160007838 | 1.77 | 67.8 | Adjuvant (A) | 2017-12-04 | 2017-12-12 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100276551 |
| 160015810 | 160007839 | 1.67 | 75.1 | Adjuvant (A) | 2016-10-06 | 2016-10-06 | Cisplatin + Etoposide (3 day) | 02 | N | EPIRUBICIN | 101421285 |
| 160015814 | 160007840 | 1.46 | 47.5 | Palliative (P) | 2017-08-16 | 2017-08-26 | PACLITAXEL | 02 | N | NB HRNBL-1 COJEC IND COURSE A | 100120593 |
| 160015816 | 160007841 | 1.52 | 47.4 | Palliative (P) | 2016-02-19 | 2016-02-29 | Doxorubicin + Ifosfamide | N | N | CISPLATIN + PEMETREXED | 101630734 |
| 160015817 | 160007842 | 1.64 | 74.6 | Palliative (P) | null | 2019-02-10 | Carboplatin + Paclitaxel (weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100532897 |
| 160015818 | 160007843 | 1.8 | 70 | Palliative (P) | 2018-10-02 | 2018-10-22 | Doxorubicin 75mg/m2 | 01 | N | LIPOSOMAL DOXORUBICIN | 101857983 |
| 160015819 | 160007844 | 1.7 | 71.5 | Palliative (P) | 2019-04-09 | 2019-05-05 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100581305 |
| 160015820 | 160007845 | null | null | Palliative (P) | 2022-03-24 | 2022-04-06 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN | 100870587 |
| 160015821 | 160007846 | 0.7 | 63.4 | Palliative (P) | 2017-12-13 | 2017-12-28 | Hydroxycarbamide | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 101751148 |
| 160015822 | 160007847 | 1.6 | 73.4 | Neo-adjuvant (N) | 2018-05-11 | 2018-05-15 | Doxorubicin 75mg/m2 | null | N | ATOMIC-MESO TRIAL | 100161542 |
| 160015823 | 160007848 | 1.5 | 68 | Palliative (P) | 2016-02-22 | 2016-02-25 | Paclitaxel 80mg/m2 day 1 8 15 | Y | N | BEVACIZUMAB | 100558380 |
| 160015825 | 160007849 | 1.74 | 92 | Curative (C) | 2018-05-06 | 2018-05-17 | Bevacizumab | 01 | N | PACLITAXEL | 101615395 |
| 160015827 | 160007850 | null | 49.4 | Neo-adjuvant (N) | 2019-01-24 | 2019-03-02 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100738285 |
| 160015828 | 160007851 | 1.59 | 76.4 | Neo-adjuvant (N) | 2019-01-12 | 2019-01-24 | NB HRNBL-1 COJEC Ind COURSE A | Y | N | ICON8B TRIAL | 101299042 |
| 160015829 | 160007852 | 1.71 | 71 | Curative (C) | 2016-07-06 | 2016-07-20 | Doxorubicin + Olaratumab | 02 | N | CISPLATIN + GEMCITABINE | 100658904 |
| 160015830 | 160007853 | 1.57 | 64.85 | Palliative (P) | 2016-06-02 | 2016-06-02 | Carboplatin AUC 6 - 10 | 02 | N | CARBOPLATIN | 101453515 |
| 160015831 | 160007854 | 1.69 | 66.1 | Palliative (P) | 2017-01-15 | 2017-01-22 | Carboplatin + Paclitaxel (3 weekly) | 2 | N | CARBOPLATIN + PACLITAXEL | 100041074 |
| 160015833 | 160007856 | 1.62 | 73.8 | Neo-adjuvant (N) | 2019-05-24 | 2019-06-10 | Cisplatin + Paclitaxel | null | N | MITOMYCIN INTRAVESICULAR | 100956787 |
| 160015835 | 160007857 | 1.73 | 63.8 | Adjuvant (A) | 2016-04-06 | 2016-04-13 | BENDAMUSTINE + RITUXIMAB | 02 | N | TRABECTEDIN | 100197309 |
| 160015836 | 160007858 | 1.67 | 74.8 | Palliative (P) | 2017-07-22 | 2017-07-23 | Liposomal Doxorubicin (Caelyx) | N | N | DA | 101478925 |
| 160015838 | 160007859 | 1.68 | 55.8 | null | 2019-02-23 | 2019-02-23 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100755358 |
| 160015842 | 160007860 | 1.74 | 118.6 | Curative (C) | 2019-02-22 | 2019-02-23 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100140786 |
| 160015844 | 160007861 | 1.8 | 61.3 | Neo-adjuvant (N) | 2019-08-30 | 2019-09-13 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101304292 |
| 160015846 | 160007862 | 1.72 | 90 | Palliative (P) | 2017-03-23 | 2017-03-27 | EW EuroEwing 2012 Arm B VDC | 02 | N | CISPLATIN + GEMCITABINE | 101784250 |
| 160015847 | 160007863 | 0 | 93.5 | Palliative (P) | 2016-08-23 | 2016-08-23 | Azacitidine | 02 | N | PACLITAXEL | 101745278 |
| 160015848 | 160007864 | 1.71 | 63.6 | Neo-adjuvant (N) | 2017-05-19 | 2017-06-21 | Carboplatin AUC 2 - 5 | 02 | 2 | DOXORUBICIN + OLARATUMAB | 101437570 |
| 160015849 | 160007865 | 0 | 46 | Palliative (P) | 2018-06-09 | 2018-06-10 | Enzalutamide | null | N | TRIAL UNSPECIFIED | 101610665 |
| 160015850 | 160007866 | 0 | 12.5 | Curative (C) | 2016-01-24 | 2016-02-05 | IVADo | 2 | N | CARBOPLATIN + GEMCITABINE | 100283529 |
| 160015851 | 160007867 | 1.61 | 78.3 | Palliative (P) | 2017-11-15 | 2018-01-25 | DOXORUBICIN | 01 | N | DOXORUBICIN | 101470115 |
| 160015854 | 160007868 | 1.72 | 76 | Palliative (P) | 2020-04-02 | 2020-04-14 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100288806 |
| 160015858 | 160007870 | 1.75 | 65 | Palliative (P) | 2019-08-18 | 2019-08-24 | Doxorubicin 75mg/m2 | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101755063 |
| 160015859 | 160007871 | 1.64 | 60.3 | Palliative (P) | 2016-04-08 | 2016-04-11 | Pemetrexed | 02 | N | CARBOPLATIN + PACLITAXEL | 100282020 |
| 160015864 | 160007872 | 1.77 | 99.3 | Palliative (P) | 2019-02-06 | 2019-02-06 | NB HRNBL-1 COJEC Ind COURSE A | 02 | N | EW EUROEWING 2012 ARM A VAI | 100802175 |
| 160015865 | 160007873 | 1.88 | 15 | Curative (C) | 2016-09-19 | 2016-10-01 | EW EuroEwing 2012 Arm A VIDE | 02 | null | LIPOSOMAL DOXORUBICIN | 100541981 |
| 160015866 | 160007874 | 1.86 | 54.6 | null | 2020-10-30 | 2020-10-30 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101677649 |
| 160015868 | 160007875 | 1.59 | 91.75 | Adjuvant (A) | 2016-06-03 | 2016-06-12 | NB Low/Interm risk guidelines Carbo/Etop | 02 | N | TRIAL | 101234707 |
| 160015872 | 160007876 | 1.56 | 98.4 | Palliative (P) | 2016-06-22 | 2016-07-02 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100425446 |
| 160015873 | 160007877 | 1.58 | 64.5 | 03 | null | 2018-06-14 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100306693 |
| 160015875 | 160007878 | 1.76 | 65.8 | 03 | 2016-12-23 | 2017-01-05 | null | Y | N | CYCLOPHOSPHAMIDE | 100721031 |
| 160015877 | 160007879 | 1.73 | 87.85 | Palliative (P) | 2018-06-01 | 2018-06-01 | IPM | N | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100123365 |
| 160015879 | 160007880 | 1.83 | 63 | Palliative (P) | 2019-11-09 | 2019-11-14 | Doxorubicin + Olaratumab | N | N | TEMOZOLOMIDE | 100196305 |
| 160015880 | 160007881 | 1.71 | null | Curative (C) | 2017-04-19 | 2017-05-16 | CARBOPLATIN | 02 | N | CARBOPLATIN | 100669712 |
| 160015881 | 160007882 | 1.74 | 115 | null | 2019-05-31 | 2019-06-12 | Hydroxycarbamide | N | N | EW EUROEWING 2012 ARM B VDC | 101553738 |
| 160015886 | 160007883 | 1.82 | 83.6 | Palliative (P) | 2021-06-08 | 2021-06-26 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | LIPOSOMAL DOXORUBICIN | 100362817 |
| 160015888 | 160007884 | 1.64 | 56.95 | Palliative (P) | 2017-07-18 | 2017-08-06 | Carboplatin AUC 2 - 5 | N | N | CARBOPLATIN | 101320242 |
| 160015893 | 160007886 | 1.68 | 57.3 | Curative (C) | 2019-06-06 | 2019-06-22 | Cisplatin + Doxorubicin | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101637409 |
| 160015895 | 160007887 | 1.75 | 68 | Curative (C) | 2019-12-13 | 2020-01-26 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100156411 |
| 160015897 | 160007888 | 1.08 | 68.6 | null | 2020-09-07 | 2020-09-12 | DOXORUBICIN | 02 | N | DOXORUBICIN | 101073902 |
| 160015898 | 160007889 | 1.55 | 104.6 | Neo-adjuvant (N) | 2017-09-12 | 2017-09-30 | DOXORUBICIN | 02 | N | DOXORUBICIN | 100851443 |
| 160015899 | 160007890 | 1.67 | 88 | Curative (C) | 2018-12-01 | 2018-12-12 | Doxorubicin 75mg/m2 | 02 | N | CISPLATIN + PEMETREXED | 100653734 |